RT journal article
T1 The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion document
A1 Candel, Francisco Javier
A1 Salavert, Miguel
A1 Cantón, Rafael
A1 Del Pozo, José Luis
A1 Galán Sánchez, Fátima
A1 Navarro, David
A1 Rodríguez, Alejandro
A1 Rodríguez, Juan Carlos
A1 Rodríguez Aguirregabiria, Montserrat
A1 Suberviola, Borja
A1 Zaragoza, Rafael
A2 BiomedicinaBiotecnología y Salud Pública
K1 Infection
K1 Critically ill patient
K1 Syndromic molecular diagnosis
K1 Multidrug resistant pathogens
K1 Septic shock
K1 sepsis
K1 bloodstream infection
AB Rapid multiplex molecular syndromic panels (RMMSP) (3 or more pathogens and time‑to‑results < 6 h) allow simultaneous detection of multiple pathogens and genotypic resistance markers. Their implementation has revolutionized the clinical landscape by significantly enhancing diagnostic accuracy and reducing time‑to‑results in different critical conditions. The current revision is a comprehensive but not systematic review of the literature. We conducted electronic searches of the PubMed, Medline, Embase, and Google Scholar databases to identify studies assessing the clinical performance of RMMSP in critically ill patients until July 30, 2024. A multidisciplinary group of 11 Spanish specialists developed clinical questions pertaining to the indications and limitations of these diagnostic tools in daily practice in different clinical scenarios. The topics covered included pneumonia, sepsis/septic shock, candidemia, meningitis/encephalitis, and off‑label uses of these RMMSP. These tools reduced the time‑to‑diagnosis (and therefore the time‑to‑appropriate treatment), reduced inappropriate empiric treatment and the length of antibiotic therapy (which has a positive impact on antimicrobial stewardship and might be associated with lower in‑hospital mortality), may reduce the length of hospital stay, which could potentially lead to cost savings. Despite their advantages, these RMMSP have limitations that should be known, including limited availability, missed diagnoses if the causative agent or resistance determinants are not included in the panel, false positives, and codetections. Overall, the implementation of RMMSP represents a significant advancement in infectious disease diagnostics, enabling more precise and timely interventions. This document addresses relevant issues related to the use of RMMSP on different critically ill patient profiles, to standardize procedures, assist in making management decisions and help specialists to obtain optimal outcomes.
PB BioMed Central Ltd
SN 1466-609X
YR 2024
FD 2024
LK http://hdl.handle.net/10498/36410
UL http://hdl.handle.net/10498/36410
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 11-nov-2026